How are you feeling today? Keep up to date on news and stories related to health care here!
Third-Quarter 2020 Worldwide Sales Were $12.6 Billion, an Increase of 1%; Excluding the Impact from Foreign Exchange, Sales Grew 2% KEYTRUDA Sales Grew 21% to $3.7 Billion Animal Health Sales Grew 9% to $1.2 Billion; Excluding the Impact from Foreign Exchange, Sales
Coronavirus-related closures in public places won’t stop virus spread in this phase of the pandemic, where at-home gatherings are contributing to cases, one White House official warned Thursday, according to a report. — FOX News
Running can do a number on our knees, a study confirms, but it can also build up cartilage. — New York Times: Top Stories
LAWRENCEVILLE, N.J.–(BUSINESS WIRE)–Asana BioSciences, a clinical stage biopharmaceutical company, announced that ASN007 clinical data on safety, efficacy and pharmacokinetics in solid tumor patients will be presented at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020) to be
Argentina, Brazil, Britain, France, India, Russia and the U.S. have helped push the global total to more than 40.7 million. In the past seven days, these countries have reported at least 100,000 new cases of the coronavirus, helping to push total cases
Data from More Than 50 Clinical and Epidemiological Abstracts Across Vaccines, HIV, Antibiotics and Antimicrobials Show the Breadth of the Company’s Commitment to Addressing the Threat of Infectious Diseases KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States
The researchers are seeking up to 90 healthy volunteers between the ages of 18 and 30. — FOX News
Italy once again ramped up coronavirus restrictions in a bid to avoid a new nationwide lockdown, as parts of the United Kingdom have already reinstated lockdowns similar to those seen in March, and Poland converted a major stadium into a field hospital
OPTIMIZE Pivotal Study 1 Year Outcomes Announced at TCT Connect NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–The Svelte® Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study. Primary and